Sionna Therapeutics (SION)

Executive Summary

Sionna Therapeutics (NASDAQ: SION) is a clinical-stage biopharmaceutical company developing small molecule drugs to treat cystic fibrosis (CF) by stabilizing the first nucleotide-binding domain (NBD1) of the CFTR protein. This novel approach targets the root cause of CF in a significant patient population. The company's pipeline includes two lead candidates: a Phase 2 trial for SION-719 as a monotherapy and a Phase 1 triple-combination trial (SION-451, SION-2222, SION-109) designed to maximize CFTR correction. Both trials are currently recruiting, with completion expected in mid-2026. Sionna went public in 2025 and has a market cap of ~$1.6 billion, reflecting investor optimism around its differentiated mechanism and potential to address unmet needs in CF, even in patients resistant to current standard-of-care modulators. The company operates out of Waltham, Massachusetts, and is focused on advancing its candidates through clinical development to become a leader in CF therapeutics.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 triple-combination trial data (SION-451, SION-2222, SION-109)60% success
• Q3 2026Phase 2 SION-719 monotherapy data readout30% success
• Q4 2026Potential partnership or financing announcement50% success